During the recent session, Coherus Biosciences Inc (NASDAQ:CHRS)’s traded shares were 2.17 million, with the beta value of the company hitting 0.54. At the last check today, the stock’s price was $2.51, reflecting an intraday gain of 8.91% or $0.21. The 52-week high for the CHRS share is $8.65, that puts it down -244.62 from that peak though still a striking 43.03% gain since the share price plummeted to a 52-week low of $1.43. The company’s market capitalization is $278.96M, and the average intraday trading volume over the past 10 days was 2.83 million shares, and the average trade volume was 6.12 million shares over the past three months.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Coherus Biosciences Inc (CHRS) registered a 8.91% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.91% in intraday trading to $2.51, hitting a weekly high. The stock’s 5-day price performance is 13.35%, and it has moved by -2.15% in 30 days. Based on these gigs, the overall price performance for the year is -60.55%. The short interest in Coherus Biosciences Inc (NASDAQ:CHRS) is 24.2 million shares and it means that shorts have 7.47 day(s) to cover.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Statistics show that Coherus Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Coherus Biosciences Inc (CHRS) shares have gone down -46.47% during the last six months, with a year-to-date growth rate more than the industry average at 83.33% against 13.40. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 69.30% this quarter and then jump 52.60% in the quarter after that. In the rating firms’ projections, revenue will increase 34.90% compared to the previous financial year.
Revenue for the current quarter is expected to be $91.98 million as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $69.69 million by the end of Jun 2024.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 4.73%. While earnings are projected to return 97.38% in 2024.
CHRS Dividends
Coherus Biosciences Inc is due to release its next quarterly earnings between May 06 and May 10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
Coherus Biosciences Inc insiders own 1.37% of total outstanding shares while institutional holders control 78.99%, with the float percentage being 80.09%. Blackrock Inc. is the largest shareholder of the company, while 221 institutions own stock in it. As of Dec 30, 2023, the company held over 12.07 million shares (or 10.84% of all shares), a total value of $30.43 million in shares.
The next largest institutional holding, with 10.36 million shares, is of Vanguard Group Inc’s that is approximately 9.30% of outstanding shares. At the market price on Dec 30, 2023, these shares were valued at $26.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of Coherus Biosciences Inc (CHRS) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 3.26 million shares. This amounts to just over 2.93 percent of the company’s overall shares, with a $8.23 million market value. The same data shows that the other fund manager holds slightly less at 2.72 million, or about 2.44% of the stock, which is worth about $6.86 million.
